// App-Quantinova.ai

: Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Researchers

Presenter

  • Adam J. Olszewski

Principal Investigators

  • Scott F. Huntington

  • Rajat Bannerji

  • Thomas A. Ollila

  • Jessica McMahon

  • Patrycja M Dubielecka

Medical Centers

  • Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI

  • Lifespan Cancer Institute, Brown University, Providence, RI

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Lifespan Cancer Institute, Alpert Medical School of Brown University, Providence, RI

  • Division of Hematology-Oncology, Warren Alpert Medical School of Brown University/Rhode Island Hospital, Providence, RI

  • Yale Cancer Center, Yale University School of Medicine, New Haven, CT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • Mucosa-associated lymphoid tissue lymphoma

  • Follicular lymphoma

  • Lymphomas

Biomarkers

  • Apparent diffusion coefficient

  • Twist-related protein 1

  • Circulating DNA

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Adaptive

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved